MAINTENANCE OF WEEK 12 RESPONSES THROUGH WEEK 52 WITH ETRASIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC 52 TRIAL

Bruce E. Sands  ¹     Severine Vermeire  ²     Marla C. Dubinsky  ²     Brian G. Feagan  ^{3, 4}     Remo Panaccione  ⁵     Vipul Jairath  ⁵     Andres Yarur  ⁶     Michael Chiorean  ⁷     Julian Panés  ⁸     Martina Goetsch  ⁹     Christopher J. Rabbat  ¹⁰     Pooja Shah  ¹¹     Joseph Wu  ¹²     Subrata Ghosh  ^13    
1 Icahn School of Medicine at Mount Sinai, New York, United States
² University Hospitals Leuven, Leuven, Belgium
³ Western University, London, Canada
⁴ Alimentiv Inc, London, Canada
⁵ University of Calgary, Calgary, Canada
⁶ Cedars-Sinai Medical Center, Los Angeles, United States
⁷ Swedish Medical Center, Seattle, United States
⁸ Formerly Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
⁹ Pfizer AG, Zürich, Switzerland
¹⁰ Pfizer Inc, New York, United States
¹¹ Pfizer Inc, Collegeville, United States
¹² Pfizer Inc, Groton, United States
¹³ APC Microbiome Ireland, College of Medicine and Health, University College Cork, Cork, Ireland

Topic
IBD

Session
Targeting immune cell trafficking in IBD (Posters)

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)